Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Biogen to acquire TMS-007
July 2018
SHARING OPTIONS:

CAMBRIDGE, Mass.—June saw the beginning of an exclusive option agreement between Biogen and TMS Co. Ltd., under which Biogen will acquire TMS-007—a plasminogen activator with a novel mechanism of action that helps to break down blood clots and is thought to inhibit inflammation at the site of thrombosis—and backup compounds. Biogen will pay TMS $4 million up front and $18 million if Biogen exercises its option. TMS also stands to receive up to $335 million in potential development and commercialization milestones, as well as tiered royalties. TMS-007 has reduced infarct volume (dead tissue due to lack of blood supply) in rodent and primate models of embolic and thrombotic stroke. A double-blind, placebo-controlled Phase 2 study is underway to determine the safety and efficacy of a single intravenous administration up to 12 hours after stroke onset in patients with acute ischemic stroke.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.